Maria Stapfer, MD
Transplant Surgery · Fullerton, CANPI 1073543146
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 98.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $7,209 and has fallen 98.5% since, to $106 in 2025.
Across 46 payments — averaging $334.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$15K
- AbbVie$136
- Histosonics, Inc.$50
- BD$36
- Davol Inc.$35
- Merck$18
- plus $14 from 1 others
What the payments were for
- Speaking & faculty fees$2,10014%
- Travel & lodging$3,94926%
- Food & beverage$5854%
- Education$8,75057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 35 | $15,095 |
| AbbVie | 6 | $136 |
| Histosonics, Inc. | 1 | $50 |
| BD | 1 | $36 |
| Davol Inc. | 1 | $35 |
| Merck | 1 | $18 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$14,320
How this compares
$15,384 in reported general payments places this provider in the 85th percentile of 56 transplant surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 25 | $48,385 |
| Pantoprazole Sodium | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $136 | $48,38525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 transplant surgery providers in California.
Other transplant surgery in Fullerton
- Elizabeth SquiersHalf Moon Bay$1.3M
- Myron TongPasadena$99K
- Robert RedfieldOrange$65K
- Yuri GenykLos Angeles$35K
- Angeles Baquerizola Jolla$28K
- Navpreet KaurLos Angeles$19K
- Gerald LipshutzLos Angeles$16K
- Steven WiselWest Hollywood$13K
- Mohd SheikhLos Angeles$9K
- Justin SteggerdaWest Hollywood$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.